Benefits
Higher bioavailability than ferrous sulfate
Stable isotope and clinical absorption studies show ferrous bisglycinate is absorbed several-fold more efficiently than ferrous sulfate in many food matrices, particularly those high in phytates and polyphenols, supporting more efficient hemoglobin response per milligram of elemental iron.
Improved gastrointestinal tolerability
Compared with ferrous sulfate at equivalent elemental iron, FerroChel® has been associated with fewer reports of nausea, constipation, metallic taste, dark stool, and abdominal discomfort. Better tolerability supports adherence over the months typically required for iron repletion.
Effective correction of iron deficiency anemia
Clinical trials in anemic women and young children have demonstrated meaningful hemoglobin and ferritin improvements with ferrous bisglycinate at typical supplemental doses, supporting use for correction of iron deficiency anemia and prevention of recurrence.
Robust absorption in plant-based diets
Because chelation protects the iron from binding inhibitors such as phytates and tannins, FerroChel® is particularly relevant for vegetarian, vegan, and high-fiber dietary patterns where non-heme iron absorption from food is otherwise low.
Less fatigue when iron stores are low
Tested as plain iron (ferrous sulfate, 80 mg iron a day), not as FerroChel. In two placebo-controlled trials of non-anaemic women with unexplained fatigue, fatigue scores fell 47.7% vs 28.8% over 12 weeks (198 women with ferritin below 50 ug/L) and 29% vs 13% over 4 weeks (144 women; only those with ferritin at or below 50 ug/L improved). Pooled trials found no gain in measured exercise capacity.
Attention and concentration support when iron is low
Studied as oral iron in general, not as FerroChel. A pooled analysis of 14 trials in school-age children, teens and women found better attention and concentration; IQ rose only in anaemic groups and pooled memory scores did not change. This is limited evidence: the trials were small, short and methodologically weak, with signs of publication bias. In 73 iron-deficient teen girls, 8 weeks of iron improved verbal learning versus placebo.
Mechanism of action
Chelated structure protects iron through the GI tract
The two glycine ligands surround the Fe²⁺ ion, forming a stable, electrically neutral chelate that resists binding to dietary phytates, polyphenols, and other absorption inhibitors. The intact chelate is transported into enterocytes via amino acid and peptide pathways, after which the iron is released for normal use.
Less generation of free radical iron in the gut lumen
Conventional iron salts liberate free Fe²⁺ in the gut lumen, which can catalyze Fenton-type reactions, irritate the mucosa, and contribute to GI side effects. The chelated form of FerroChel® reduces free luminal iron, plausibly explaining the improved tolerability profile.
Use of amino acid transporters rather than DMT1 alone
Beyond classical DMT1-mediated non-heme iron uptake, the bisglycinate chelate appears to enter enterocytes partly via amino acid and dipeptide transporters. This alternative uptake pathway helps explain higher absorption rates that are less dependent on competing dietary minerals.
Regulated absorption by body iron status
Like other non-heme iron forms, ferrous bisglycinate absorption is downregulated by hepcidin when body iron stores are adequate and upregulated in iron deficiency. This natural feedback reduces (but does not eliminate) the risk of iron overload at therapeutic supplemental doses.
Clinical trials
Stable isotope iron absorption study comparing ferrous bisglycinate and ferric trisglycinate fortification of maize meals against ferrous sulfate in adults with varying iron status. Published in American Journal of Clinical Nutrition.
Adults with a range of iron stores; controlled meal-based absorption study.
Ferrous bisglycinate absorption from whole maize was several-fold higher than ferrous sulfate at equivalent iron doses, and absorption was inversely related to body iron status — consistent with normal regulatory control while delivering meaningfully more iron per milligram of fortificant.
Matched comparative trial (40 infants and young children) of ferrous bisglycinate versus ferrous sulfate for treatment of iron deficiency anemia; the report describes matched assignment to two groups, not randomization. Outcomes: hemoglobin response, GI tolerability.
Infants and young children with iron deficiency anemia.
Ferrous bisglycinate produced effective hemoglobin recovery with notably higher relative bioavailability than ferrous sulfate, supporting clinical use of bisglycinate for pediatric iron repletion with comparable or improved tolerability.
Human iron absorption study evaluating bioavailability of iron bisglycinate compared with ferrous sulfate in breakfasts enriched with phytate and polyphenol-rich foods. Published in the Journal of Nutrition.
Adult volunteers; controlled meal-based absorption study.
Iron bisglycinate absorption was substantially less impaired by phytates and polyphenols than ferrous sulfate. The bisglycinate form preserved meaningful absorption in inhibitor-rich meals, supporting its use in plant-based and high-fiber dietary patterns where non-heme iron absorption is otherwise low.